IL285719B - A method for the production of a toxin-binding protein in a plant cell or a whole plant - Google Patents

A method for the production of a toxin-binding protein in a plant cell or a whole plant

Info

Publication number
IL285719B
IL285719B IL285719A IL28571921A IL285719B IL 285719 B IL285719 B IL 285719B IL 285719 A IL285719 A IL 285719A IL 28571921 A IL28571921 A IL 28571921A IL 285719 B IL285719 B IL 285719B
Authority
IL
Israel
Prior art keywords
protein
toxin
plant
binder
cell
Prior art date
Application number
IL285719A
Other languages
English (en)
Hebrew (he)
Other versions
IL285719A (en
Inventor
MAGY Bertrand
Houry Max
Original Assignee
Atb Therapeutics
MAGY Bertrand
Houry Max
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atb Therapeutics, MAGY Bertrand, Houry Max filed Critical Atb Therapeutics
Publication of IL285719A publication Critical patent/IL285719A/en
Publication of IL285719B publication Critical patent/IL285719B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL285719A 2019-02-18 2020-02-18 A method for the production of a toxin-binding protein in a plant cell or a whole plant IL285719B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Publications (2)

Publication Number Publication Date
IL285719A IL285719A (en) 2021-10-31
IL285719B true IL285719B (en) 2022-07-01

Family

ID=65717705

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285719A IL285719B (en) 2019-02-18 2020-02-18 A method for the production of a toxin-binding protein in a plant cell or a whole plant

Country Status (11)

Country Link
US (1) US20220090113A1 (https=)
EP (2) EP4733324A2 (https=)
JP (2) JP7150999B2 (https=)
KR (1) KR102398485B1 (https=)
CN (2) CN115925972A (https=)
BR (1) BR112021016348A2 (https=)
CA (1) CA3128793C (https=)
ES (1) ES3055338T3 (https=)
IL (1) IL285719B (https=)
WO (1) WO2020169620A1 (https=)
ZA (1) ZA202105654B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
CN115768897B (zh) * 2020-05-28 2026-03-27 中外制药株式会社 改进的颗粒酶b变体
JP7818834B2 (ja) 2020-08-17 2026-02-24 エーティービー セラピューティクス リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2705289A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
US20130145502A1 (en) 2010-06-09 2013-06-06 Pioneer Hi-Bred International, Inc. Regulatory sequences for modulating transgene expression in plants
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Also Published As

Publication number Publication date
CA3128793C (en) 2023-02-28
EP3927831B1 (en) 2025-11-12
US20220090113A1 (en) 2022-03-24
KR102398485B1 (ko) 2022-05-16
ZA202105654B (en) 2023-04-26
BR112021016348A2 (pt) 2021-11-23
WO2020169620A1 (en) 2020-08-27
CA3128793A1 (en) 2020-08-27
EP3927831C0 (en) 2025-11-12
KR20210120051A (ko) 2021-10-06
ES3055338T3 (en) 2026-02-11
CN113728107B (zh) 2022-06-24
EP4733324A2 (en) 2026-04-29
JP2022176933A (ja) 2022-11-30
EP3927831A1 (en) 2021-12-29
JP2022518614A (ja) 2022-03-15
JP7728587B2 (ja) 2025-08-25
CN115925972A (zh) 2023-04-07
IL285719A (en) 2021-10-31
CN113728107A (zh) 2021-11-30
JP7150999B2 (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
CA3128793C (en) Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
Ko et al. Production of antibodies in plants: approaches and perspectives
Marusic et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells
De Meyer et al. Comparison of VHH‐Fc antibody production in A rabidopsis thaliana, N icotiana benthamiana and P ichia pastoris
US7531522B2 (en) Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
Krittanai et al. Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
US20230310557A1 (en) Recombinant immunotoxin comprising a ribotoxin or rnase
US20250387478A1 (en) Recombinant immunotoxin comprising a ribosome inactivating protein
US20090041776A1 (en) Production of cancer-specific antibodies in plants
Zagorskaya et al. Recombinant monoclonal antibodies synthesized in plant expression systems: problems and prospects
Dorokhov et al. Plant platform for therapeutic monoclonal antibody production
Schouten Plantibodies: requirements for expression and subcellular targeting
KR20250049549A (ko) CD79b에 대한 인간화된 항체
Lonoce Production of tumour-targeting antibodies in hairy root cultures
Westerhof Plants as a production platform for high-value proteins
Stark Targeted expression of the anti-HIV microbicide lectin griffithsin in maize and tobacco
Faso Plant-based production of Cyanovirin-N, a cyanobacterial protein with anti-HIV properties